Tyra Biosciences 2021 Investor Presentation

Tyra Biosciences is developing next-generation oncology drugs designed to target acquired drug resistance with improved tolerability. The company's pipeline includes FGFR-selective inhibitors addressing FGFR3, FGFR2, RET, FGFR4, and achondroplasia indications.